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Retrospective analyses in non-randomised cohorts suggest
that regimens containing ﬂudarabine/Ara C and/or idarubicin/
ara C may be more effective than daunorubicin/AraC (DA)-
containing regimens in cases of acute myeloid leukaemia (AML)
overexpressing p-glycoprotein (Pgp). We prospectively mea-
sured Pgp protein and function by ﬂow cytometry in CD45-
gated blasts from 434 AML15 trial patients randomised to
remission induction therapy with two courses of FLAG-Ida or
DA±etoposide (DA/ADE). In all, 34% were positive for Pgp
protein and 38% for function. Pgp protein-positive cases had a
higher incidence of resistant disease (14% vs 5%), adjusted
odds ratio 2.67 (1.14–6.24). There was a trend towards a higher
cumulative incidence of relapse at 5 years for Pgp-positive
cases (46% vs 55%), adjusted hazard ratio 1.42 (0.98–2.07)
(P¼0.06). For patients treated with FLAG-Ida, the complete
remission (CR) rate was 86% for both Pgp-positive and
Pgp-negative patients. In patients treated with DA/ADE, 78%
of Pgp-positive and 90% of Pgp-negative cases achieved CR
(P¼0.06). In analyses of overall survival, there was no
interaction between treatment received and Pgp expression.
Data for Pgp function followed similar trends. Our data suggest
that FLAG-Ida may improve the remission rate for Pgp-positive
AML, but the malignant clone is reduced rather than eradicated
such that the relapse rate remains high in Pgp-positive patients.
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Introduction
P-glycoprotein (Pgp) is expressed in the plasma membrane of
blast cells in B40% patients with acute myeloid leukaemia
(AML).
1 Pgp functions as a drug efﬂux pump that can account for
the failure of many drugs to reach their intracellular targets.
Such drugs include the common AML-treatment drugs daunor-
ubicin and etoposide. Overexpression of Pgp by AML blasts is
well established as a determinant of resistance to remission-
induction chemotherapy, and confers inferior disease-free
survival and overall survival (OS) in patients receiving
conventional anthracycline-containing remission-induction
regimens.
2,3
Attempts to improve outcome by including a Pgp-reversal
agent in clinical trials have largely been unsuccessful.
4 Some
clinical beneﬁt was shown in a study in relapsed patients from
the Southwest Oncology Group using cyclosporin as a
modulator of daunorubicin given by continuous infusion.
5 This
trial showed a superior response rate and OS in relapsed patients
in the cyclosporin arm. Cyclosporin also appeared to have some
beneﬁt in a non-randomised comparison of previously untreated
elderly patients, with an improved complete remission (CR) rate
for Pgp-positive patients treated with the modulator.
6 Cyclo-
sporin is thought not to be an ideal choice as a modulator
because of its immunosuppressive properties and its potential
for nephrotoxicity. The cyclosporin analogue PSC-833 had the
potential beneﬁt of less immunosuppression and renal toxicity,
but trials of PSC-833 have failed to show beneﬁt.
7–11 The third-
generation agent zosuquidar has also failed to show signiﬁcant
beneﬁt in a randomised trial.
12
The FLAG (Fludarabine, Ara-C plus G-CSF) regimen with or
without the addition of idarubicin (FLAG-Ida) has featured in
several studies as induction therapy for relapsed AML and for
patients who failed to achieve remission with standard
daunorubicin and Ara-C (DA) regimens,
13,14 and has been a
successful strategy in refractory AML with documented
Pgp-induced multidrug resistance.
14 The cytotoxicity of FLAG
is from the individual toxicities of ﬂudarabine and Ara-C and
from the potentiation of Ara-C toxicity by ﬂudarabine and
G-CSF. As ﬂudarabine and Ara-C are not Pgp-substrate drugs,
this combination may be effective at bypassing Pgp-related
resistance mechanisms in primary AML cells. Pgp-related FLAG
toxicity has also been studied in vitro: using the MRK16
antibody to deﬁne Pgp positivity, we found a clear advantage
for DA treatment in Pgp-negative AML samples but, in contrast,
Pgp-positive AML cells were found to be more responsive to
FLAG than to DA.
15 Furthermore AML cells with the highest
expression of Pgp had the greatest differential response to
FLAG.
15 Furthermore, a group of centres, which had been using
FLAG for remission induction in de novo AML, published a
case–control study of Pgp and induction regimens with and
without ﬂudarabine, which suggested that this agent was of
beneﬁt in Pgp-positive cases.
16 Idarubicin is also of potential
beneﬁt in Pgp-positive AML cases. Although the drug is efﬂuxed
by Pgp, its increased lipophilicity and thus enhanced uptake
leads to greater toxicity compared with daunorubicin in drug-
resistant cells.
17,18 Pgp did not affect clinical responses
to idarubicin-containing remission-induction therapy
19 and
appeared not to confound response to idarubicin monotherapy
in heavily pre-treated patients.
20
One study of FLAG with idarubicin (FLAG-Ida) used as ﬁrst-
line AML-induction therapy produced a CR rate of 82%,
21
conﬁrming the efﬁcacy of this regimen and providing a
rationale for comparison with daunorubicin and Ara-C (DA), as
FLAG-based regimens had never been compared with DA in a
randomised way for remission-induction therapy in de novo
AML. This was one of the principal questions addressed by the
MRC AML15 Trial. This trial therefore represented an opportunity
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Patients in AML15 were randomised to receive DA, ADE or
FLAG-Ida with an additional randomisation to Mylotarg.
Methods
Patients
The AML15 trial was open to all patients with de novo or
secondary AML aged 15–60 years, and also to patients aged 60
years or over for whom intensive therapy was considered
appropriate. Amendments were made to the AML15 protocol
during the course of the trial, but samples used in this study were
collected before June 2006 which covered a period when the
remission-induction randomisations (in non-M3 patients) were to
receive one of three induction regimens ADE, DA or FLAG-Ida for
the ﬁrst two courses of treatment with an additional randomisa-
tion to Mylotarg (3mg/m
2) given on day 1 of course 1. Details,
including a cohort diagram, are published elsewhere.
22 Results
of the randomisation to Mylotarg are not included in the current
analysis; previous work showed no interaction for outcomes of
the Mylotarg randomisation with Pgp.
22 Patients not scheduled
for transplant were randomised after course 2 to two further
courses comprising amsacrine, Ara-C, etoposide (MACE) and
mitozantrone and Ara-C (MidAc) or high-dose Ara-C at one of
two doses (3 or 1.5g/m
2), in a 2:1:1 randomisation, and to
receive or not a ﬁfth course of chemotherapy.
Laboratory analysis
Presentation of bone marrow or peripheral blood samples
(n¼464) for Pgp analysis were taken into preservative-free
heparin or into EDTA tubes and sent to one of two laboratories
in Nottingham and Cardiff between 2002 and 2006. Pgp was not
measured in patients with M3 AML. Children were also
excluded due principally to the large number of tests that
needed to be performed on limited material, but also because
prognostically signiﬁcant Pgp overexpression is uncommon in
pediatric cases.
23,24 Details of the methodology and of the
reproducibility studies undertaken to ensure agreement between
the two laboratories are published elsewhere.
1,25,26 Brieﬂy Pgp
protein was measured using the MRK16 antibody and function
was measured using modulation by PSC-833 of rhodamine 123
retention. Cells were counterstained with CD45 to identify the
blast (CD45low/side scatter low) population in ﬂow-cytometric
analysis.
Deﬁnition of endpoints
The outcome deﬁnitions used follow the international guidelines
of Cheson et al.
27 In the original protocol, patients did not
require peripheral count recovery to achieve CR; however, in
this report, CR required neutrophil recovery to 1.0 10
9/l and
platelets to 100 10
9/l, without evidence of extramedullary
disease. Patients who achieved CR according to the protocol,
but without recovery are denoted here as CRi. Remission failures
were classiﬁed by the investigating clinician as due to induction
death (death related to treatment and/or hypoplasia within 30
days), or resistant disease (failure to eliminate disease, including
partial remissions). Where clinician evaluation was not avail-
able, deaths within 30 days were deemed induction death and
other failures resistant disease. All percentages are quoted at
5 years.
Statistical analysis
Details of the clinical endpoints are as published previously
22
and are in line with IWG Guidelines.
27 Mantel–Haenszel and
w
2-tests were used to test for differences in demographical and
clinical data by Pgp status. Kaplan–Meier curves were con-
structed for survival data and compared by means of the log-
rank test. Multivariate Cox models were used to analyze
cumulative incidence of relapse and OS. Multivariate models
were adjusted for factors as speciﬁed and interactions were
tested using the deviance. Surviving patients were censored at
1 January 2009, with follow-up complete for 97% of patients.
Hazard ratios and 95% conﬁdence intervals are quoted for
endpoints. In all cases a ratio of o1 indicates beneﬁt for higher
Pgp levels. All P-values are two-tailed.
Results
Demographics and laboratory correlates
Demographic data are displayed in Table 1. Patients were
primarily under 60, although 13% of the cohort studied for Pgp
was older. Of the 464 samples processed, there were sufﬁcient
viable cells to measure protein and/or function in 434 and both
in 348. Pgp protein was measured in 368 samples and Pgp
function in 412. in all, 34% of cases were positive for Pgp
protein and 38% for function (23% low and 15% high). The
median age of this cohort was 48. Table 1 incorporates an
examination of factors previously indicated to be associated
with Pgp expression, such as age, white cell count, cytogenetics
and secondary AML.
1,28 In this relatively young cohort, with less
secondary AML or adverse cytogenetics than in the elderly, Pgp
positivity remained associated with age (P¼0.01) and with a
lower white count (P¼0.002) (Table 1). Comparison with
contemporaneous adult trial patients with non-APL AML not
included in this data set (n¼1166), demonstrated that there
were no signiﬁcant differences in age, sex, performance status or
cytogenetic group between patients with data on Pgp and those
without, although patients in this study were slightly less likely
to have secondary disease (6% vs 9%, P¼0.05) and had slightly
higher white blood cell count (median 13.2% vs 9.7, P¼0.02)
than those in the rest of AML15. Outcomes, however, were
similar between groups.
Effect of Pgp on outcome in the entire cohort
Overall, Pgp was associated with an inferior CR rate in
unadjusted analysisFodds ratio (OR) 1.91 (1.03–3.55)
P¼0.04, Table 2, but did not signiﬁcantly affect the CR rate
after adjustment for age, WBC, sex, secondary disease,
performance status and cytogenetics (standard co-variates in
MRC AML Trial analysis).
22 As Pgp might be expected to affect
the cellular response to chemotherapy, but not to have an effect
on induction deaths, we also studied primary resistant disease.
Pgp protein-positive cases had a higher incidence of primary
resistant disease (14% vs 5%), adjusted OR 2.67 (1.14–6.24)
P¼0.02, Table 2.
There was a trend towards a lower cumulative incidence of
relapse at 5 years for Pgp-negative cases (46% vs 55%, adjusted
hazard ratio 1.42; 0.98–2.07, P¼0.06), but this did not translate
into a signiﬁcant survival beneﬁt (Table 2). Results for Pgp
function were similar, although the association with primary
resistant disease was lost in the adjusted data set, whereas a
marked association was noted between Pgp function and poor
relapse-free survival (Table 3 and Figure 1).
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Pgp-positive and -negative AML
The impact of individual induction regimens on initial response
is shown in Table 4. For patients receiving DA/ADE-induction
therapy the CR rate was lower in PgpþAML compared
with Pgp-negative cases (78% compared with 90%, OR 2.74
(1.27–5.89) P¼0.01). In contrast the CR rate for FLAG-Ida was
86% for both Pgp-positive and -negative patients (OR 0.97
(0.34–2.78) P¼1.0). The adjusted P-value for the interaction
between Pgp and induction treatment for CR rate was 0.06.
For patients receiving ADE/DA, the incidence of primary
resistant disease was 6% in the Pgp-negative cohort and 18% in
Pgp-positive cases, OR 3.84 (1.55–9.53), P¼0.004, whereas no
signiﬁcant difference was observed between Pgp-positive and -
negative cases treated with FLAG/Ida. The P-value for inter-
action was 0.8, but with such a low incidence of primary
resistant disease in the trial, this comparison was underpowered
for statistical analysis. There were no signiﬁcant interactions
association between Pgp function and CR rate.
We have reported that for all patients entered into the AML15
trial the cumulative incidence of relapse was lower for patients
given FLAG-Ida compared with ADE.
29 However, the cumula-
tive incidence of relapse rate for Pgp-positive patients in both
arms was greater than for Pgp-negative patients: the adjusted
Table 2 Responses of the entire cohort (n¼348) according to Pgp protein status
Protein negative (%) Protein positive (%) Unadjusted OR/HR,
95% CI; P-value
Adjusted OR/HR,
95% CI; P-value
CR/CRi 89 81 1.91 (1.03–3.55); 0.04 1.51 (0.78–2.92); 0.2
Resistant disease 5 14 3.35 (1.50–7.46); 0.003 2.67 (1.14–6.24); 0.02
5-year OS 46 33 1.27 (0.95–1.71); 0.10 1.13 (0.82–1.55); 0.5
5-year RFS 45 32 1.32 (0.97–1.01); 0.08 1.34 (0.95–1.88); 0.09
5-year CIR 46 55 1.33 (0.94–1.88); 0.11 1.42 (0.98–2.07); 0.06
Abbreviations: CI, conﬁdence interval; CIR, cumulative incidence of relapse; CR, complete remission; HR, hazard ratio; OR, odds ratio; OS, overall
survival; Pgp, p-glycoprotein; RFS, relapse-free survival.
Table 1 Demographic data
Pgp protein (number) Pgp function (number)
Negative Positive P Negative Low High P
Age 0.01
a 0.05
a
o15 0 0 1 0 0
15–29 42 19 32 25 4
30–39 42 13 43 7 6
40–49 56 23 57 24 14
50–59 83 44 95 27 23
60–69 21 25 26 12 16
70+ 0 0 0 0 0
Sex 0.03 0.07
a
Female 126 49 129 44 24
Male 118 75 125 51 39
Performance status 0.18
a 0.11
a
0 156 88 154 69 42
17 8 3 3 8 7 2 2 2 0
26 1 6 1 1
33 2 5 3 0
41 0 1 0 0
Secondary disease 0.6 0.2
a
No 233 120 246 91 59
Yes 11 4 8 4 4
WBC 0.002
a o0.0001
a
o10 71 57 69 48 42
10–49.9 92 40 98 31 12
50–99.9 43 18 47 10 7
100+ 36 9 38 6 2
Unknown 2 0 2 0 0
Cytogenetics 0.4
a 0.08
a
Favourable 35 20 29 26 4
Intermediate 155 65 166 42 33
Adverse 17 17 15 12 12
Unknown 37 22 44 15 14
aMantel–Haenszel test for trend: all others test for heterogeneity.
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function (Figure 2).
There was no signiﬁcant interaction between Pgp protein or
function and treatment group affecting OS (Figure 3): the
adjusted P-values for the interaction were 0.4 for protein and 0.8
for function.
Discussion
A previous study of the interaction between Pgp and regimens
with or without ﬂudarabine (comprising ﬂudarabine, AraC,
idarubicin±etoposide) adopted an age-matched case–control
strategy and found an improved CR rate, OS and disease-free
survival for Pgp-positive patients with regimens containing
ﬂudarabine.
16 In the randomised AML15 trial, results on CR are
in agreement with this and show a CR/CRi rate of 86% for Pgp-
positive patients with FLAG-Ida, which was the same as that seen
in Pgp-negative AML. In contrast, patients receiving induction
regimens incorporating the Pgp substrates daunorubicin and
etoposide (DA/ADE) had a lower CR rate if they were Pgpþ.
This is the second randomised controlled trial in de novo AML to
have shown a beneﬁt for an intervention in the Pgpþ group.
Previously, quinine was also shown to improve the CR rate but not
OS in Pgpþ AML patients.
30 Other strategies attempted,
particularly the use of Pgp inhibition with PSC833 or zosuquidar,
have failed to improve outcomes in this group of patients.
7–12
Regarding relapse, results for AML15 previously reported
showed that FLAG-Ida resulted in a reduced relapse rate overall
compared with DA/ADE.
29 Both Pgp-positive and -negative
patients beneﬁted in this respect from FLAG-Ida treatment, but
in contrast to the case–control study, we found a signiﬁcant
interaction between Pgp and treatment received with respect to
relapse rate, with Pgp-positive patients having a higher relapse
rate than Pgp-negative patients in both treatment arms.
Furthermore there was no interaction between Pgp and
treatment received in effect on OS. Thus the use of FLAG-Ida
induction in Pgp-positive cases induces a slight shift in initial
efﬁcacy, such that efﬁcient clonal reduction results in improved
CR for this subgroup, but these patients have an increased
frequency of relapse with a consequent lack of effect on OS.
These data suggest that in the most chemoresistant samples, the
leukaemic clone is reduced rather than eradicated, such that
relapse is high in these cases. Pgp is not necessarily over-
expressed in all leukaemic stem and progenitor cells. However,
we have previously determined that Pgp expression in the
CD34þCD38 subset, which contains the leukaemia initiating
cells, correlates strongly with expression in the sample as a
whole, suggesting that when a sample is Pgp positive, relapse is
likely to be driven by Pgp-positive cells within this sub-
population.
31 However, factors driving chemoresistance in the
MRD cells of Pgp-negative samples remain to be determined.
The suggestion that Pgp is acquired during the course of
remission-induction chemotherapy is a possibility, but remains
unproven.
11,32,33 We investigated an alternative explanation for
the altered CR and relapse rates in Pgpþ patients treated with
ﬂudarabine-based regimens, namely that post-remission regi-
mens, including use of stem cell transplants, may have differed.
Consolidation regimens were randomised in the AML15 trial,
although uptake in the FLAG-Ida arm of the trial was lower than
in the ADE/DA part of the trial. Overall within AML15, as was
demonstrated in the initial report of the results,
29 signiﬁcantly
improved relapse-free survival was obtained with FLAG-Ida
compared with daunorubicin-containing regimens. In the study
reported here, rates of allogeneic transplantation were similar
between groups (ADE/DA 20%, FLAG-Ida 15%, P¼0.2). We
therefore consider it unlikely that the results seen arise out of
differences in post-remission treatment, although numbers are
too small to rule this out with absolute certainty.
Slight distinctions between Pgp protein and function have
been noted in this study and we have commented on this
previously.
1 We used PSC-833 in our functional assay and
although this is more speciﬁc than other modulators in the
literature, it has not been studied in genetic models of all 49
ABC transporters, and other efﬂux pumps may be affected in this
Table 3 Responses of the entire cohort (n¼412) according to Pgp function status
Function
negative (%)
Function
low (%)
Function
high (%)
Unadjusted OR/HR,
95% CI; P-value
Adjusted OR/HR,
95% CI; P-value
CR/CRi 87 87 78 1.30 (0.92–1.84); 0.14 1.13 (0.75–1.70); 0.6
Resistant disease 6 6 17 1.78 (1.16–2.76); 0.009 1.45 (0.88–2.40); 0.14
5-year OS 46 42 28 1.17 (0.99–1.39); 0.06 1.12 (0.93–1.36); 0.3
5-year RFS 46 34 24 1.26 (1.06–1.51); 0.01 1.26 (1.03–1.54); 0.02
5-year CIR 47 52 63 1.24 (1.02–1.51); 0.03 1.27 (1.02–1.59); 0.03
Abbreviations: CI, conﬁdence interval; CIR, cumulative incidence of relapse; CR, complete remission; HR, hazard ratio; OR, odds ratio; OS, overall
survival; Pgp, p-glycoprotein; RFS, relapse-free survival.
Figure 1 Relapse free survival stratiﬁed by (a) Pgp protein and (b) Pgp
function.
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was on relapse, so the possibility that the leukaemic stem cells
that drive relapse have additional pumps affected in the
functional assay is logical but completely speculative.
Our study shows a high CR/CRi rate in AML15 Pgp-positive
patients compared with other studies reported in the literature.
Table 5 represents a compilation of remission data, from studies
in which the Pgp status of patients is known. Some studies
comprised a wide range of patient ages, so we have selected
those with a median age o60 to afford a reasonable comparison
with our data. All patients were treated with chemotherapy
containing ara-C and an anthracycline. The CR/CRi rate for Pgp-
positive adult patients in AML15 receiving FLAG-Ida was over
10% higher than that reported in these historical controls.
Only one report of those listed in Table 5 failed to show a
difference in CR rate between Pgp-positive and -negative
patients: this study is notable in that idarubicin was used in
preference to daunorubicin, and ﬂudarabine was not included in
the treatment protocol.
19 This serves as a reminder that the
effects we have observed in the current study maybe a result of
the interaction between ﬂudarabine and idarubicin or to either
of these drugs individually. Prospective analysis of Pgp in
clinical specimens has been hampered by a literature in the
1990s showing that Pgp is difﬁcult to measure. More recently,
however, multi-centre analysis of AML samples has shown that
reliable, quick measurements of Pgp function are feasible.
1,26
We hope that other groups using ﬂudarabine and idarubicin will
consider measuring Pgp in their patients.
In conclusion our data indicate that FLAG-Ida may improve
the remission rate for Pgp-positive AML, but the malignant
clone is reduced rather than eradicated such that the relapse
rate remains high in Pgp-positive patients, irrespective of
Table 4 Response rates stratiﬁed by treatment arm
ADE/DA FLAG P-value for interaction
CR/CRi
Protein negative (%) 90 (142/158) 86 (74/86) Unadjusted: 0.1
Protein positive (%) 78 (62/80) 86 (38/44) Adjusted: 0.06
OR and 95% CI 2.74 (1.27–5.89) 0.97 (0.34–2.78)
Unadjusted P-value (protein) P¼0.01 P¼1.0
Function negative (%) 87 (141/163) 87 (78/90) Unadjusted: 0.2
Low function (%) 89 (57/64) 84 (26/31) Adjusted: 0.15
High function (%) 71 (30/42) 90 (19/21)
OR and 95% CI (per level) 1.49 (0.99–2.26) 0.92 (0.47–1.79)
Unadjusted P-value (function) P¼0.06 P¼0.8
Resistant disease
Protein negative (%) 6 (9/158) 3 (3/86) Unadjusted: 0.5
Protein positive (%) 18 (14/80) 7 (3/44) Adjusted: 0.8
OR and 95% CI 3.84 (1.55–9.53) 2.12 (0.38–11.89)
Unadjusted P-value (protein) P¼0.004 P¼0.4
Function negative (%) 8 (13/163) 2 (2/90) Unadjusted: 0.8
Low function (%) 6 (4/64) 6 (2/31) Adjusted: 0.9
High function (%) 24 (10/42) 5 (1/21)
OR and 95% CI per level 1.81 (1.12–2.94) 1.60 (0.55–4.68)
Unadjusted P-value (function) P¼0.02 P¼0.4
Abbreviations: CI, conﬁdence interval; CR, complete remission; OR, odds ratio.
Figure 2 Relpase risk stratiﬁed by treatment, Pgp protein and Pgp function. (a) Pgp protein, DA/ADE; (b) Pgp function, DA/ADE; (c) Pgp protein,
FLAG-Ida; and (d) Pgp function, FLAG-Ida.
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obtained with FLAG-Ida in Pgp-positive AML may permit more
patients to progress to allogeneic transplantation in ﬁrst CR.
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